Choosing a Calcium Preparation: Understanding LiZhiZhu® Compound Calcium Carbonate Granules
Explore calcium dissolution, LiZhiZhu® ingredients, complexation and inclusion technologies, medicine identity, research and label information. Compare calcium carbonate D3 products, effervescent granules and historical approvals.
When choosing a calcium preparation, readers often consider calcium content, dissolution and absorption. Calcium in a preparation needs to dissolve before it can be absorbed in the intestine. Using the prescription medicine LiZhiZhu® Compound Calcium Carbonate Granules as an example, this article explains its ingredients, formulation technology, research and medicine information.
Compound Calcium Carbonate Granules is a prescription medicine. Use it according to the product label and the prescribing physician’s instructions.
1. Why calcium preparations need to dissolve
Calcium carbonate contains a high proportion of elemental calcium, about 40%, but has low water solubility. Gastric acid supports its dissolution. Gastric acidity, age, diet and medicines can influence dissolution and absorption, so formulation characteristics belong alongside nutritional needs and health in the choice of a preparation.
Reconstitution illustrates the process. Put the granules in a cup, add approximately 50–60 mL of cooled boiled water and wait about 5–8 minutes for the bubbles to disappear before taking it. The small bubbles come from the reaction between calcium carbonate and the weak acid citric acid in the excipients, which releases carbon dioxide. At the same time, citric acid acts as a complexing ligand and forms a more water-soluble calcium–citrate complex in solution. This is the complexation technology described in the formulation materials and the 2023 study, allowing dissolution to begin before the preparation reaches the stomach. Gas formation and complexation occur during the same reconstitution process: gas formation is an observable reaction, while complexation contributes to the dissolution characteristics.
The calcium source in the medicine remains calcium carbonate. Citric acid is a complexing ligand among the excipients; calcium citrate is not added as a medicinal ingredient. Complexation changes the dissolution pathway while the original calcium source remains the same.
The second formulation technology concerns vitamin D3 stability. Vitamin D supports calcium absorption. In this preparation, β-cyclodextrin is used to form an inclusion complex with vitamin D3. The 2023 pharmaceutical study observed improved stability. Complexation addresses calcium dissolution, and inclusion addresses vitamin D3 stability.
2. Product identity and indications in the label
Rickets is explicitly included among the conditions listed in the product’s indications. The full indication is broader:
For the prevention and treatment of calcium deficiency, including osteoporosis, tetany, impaired bone development and rickets, and for calcium supplementation in pregnancy, breastfeeding and postmenopausal women.
The indication is framed around calcium deficiency, with rickets listed as one example. This distinction helps readers understand both the specific conditions named in the label and the overall purpose of the medicine.
The main product information is summarized below.
| Item | Information |
|---|---|
| Generic name | Compound Calcium Carbonate Granules |
| Brand | LiZhiZhu® |
| Manufacturer | Wuhan Ximo Pharmaceutical Co., Ltd. |
| Approval number | H20173214 |
| Medicine classification | Prescription medicine (RX) |
| Strength | Each 3.4 g sachet: calcium carbonate 0.75 g (equivalent to calcium 0.3 g) + vitamin D3 62.5 IU |
| Appearance / shelf life | White and off-white granules / 24 months |
| Label revision date | 2022-03-04 |
The label directs users to put the granules in a cup, add approximately 50–60 mL of cooled boiled water and take it immediately after the bubbles disappear, after about 5–8 minutes. It states 500–1000 mg daily, expressed as calcium: adults, 1 sachet 2–3 times a day; children, 1 sachet 1–2 times a day, or as directed by a physician.
3. Four comparisons when choosing a preparation
The following comparisons distinguish similar product names, approval numbers, formulations and individual medicine information.
Compare calcium carbonate D3 products
Comparison 1: Calcium carbonate D3 products. LiZhiZhu is one specifically approved medicine; calcium carbonate D3 products form a category containing multiple approved medicines. Compare the individual products rather than treating the category as one medicine.
| Comparison | LiZhiZhu® Compound Calcium Carbonate Granules | Calcium carbonate D3 products |
|---|---|---|
| Product identity | One specifically approved medicine | A category containing several approved medicines |
| Medicine classification | Prescription medicine (RX) | Prescription or OTC status is specified for each product |
| Dissolution pathway | Complexation: citric acid and calcium form a water-soluble complex during reconstitution | Depends on the specific product |
| Vitamin D3 formulation | β-Cyclodextrin inclusion, with improved stability | Depends on the specific product |
| Indications | Prevention and treatment of calcium deficiency, including osteoporosis, rickets and calcium supplementation in pregnancy and breastfeeding | Specified in each product label |
| Research and credentials | 2019 preclinical study; 2021 meta-analysis (8 studies / 840 children); 2025 systematic review; 2021 Hubei Science and Technology Progress Award, Second Prize | Research varies by product |
Three formulation features organize the information on LiZhiZhu. Complexation starts the dissolution process during reconstitution. β-Cyclodextrin inclusion improves vitamin D3 stability. Published research includes preclinical experiments, a meta-analysis and a subsequent systematic review.
The 2019 preclinical study compared formulations in vitro and in mice. Calcium absorption was comparable in untreated mice. After omeprazole-induced gastric acid suppression, absorption did not significantly decline with the compound granules, while it decreased with the D3 comparator used in the study. These findings describe the formulations in the experimental conditions studied.
Distinguish effervescent granules
Comparison 2: Compound Calcium Carbonate Effervescent Granules. The similar generic names describe two different medicines. Their approval numbers, manufacturers and product labels distinguish them.
| Comparison | Compound Calcium Carbonate Granules (H20173214) | Compound Calcium Carbonate Effervescent Granules (H20040896) |
|---|---|---|
| Brand | LiZhiZhu® | Gai Di Xin |
| Approval number | H20173214 | H20040896 |
| Manufacturer | Wuhan Ximo Pharmaceutical Co., Ltd. | Shandong Dyne Marine Biopharmaceutical |
| Medicine classification | Prescription medicine | Non-prescription medicine (OTC) |
| Strength per sachet | 3.4 g (calcium 0.3 g / vitamin D3 62.5 IU) | 1.5 g (calcium 0.15 g / vitamin D3 31.25 IU) |
| Key contraindications and precautions | Hypercalcemia, hypercalciuria, vitamin D excess, hyperphosphatemic renal rickets and concurrent digitalis treatment | Hypercalcemia and hyperuricemia; patients with kidney stones require physician guidance |
Check both the full generic name, including the word “effervescent” where present, and the approval number.
Distinguish historical approval H20070183
Comparison 3: The historical approval H20070183. The generic name is the same, but the product identity is different. Older online records describe Compound Calcium Carbonate Granules sold as Li Xiang Zhu under approval H20070183, associated with the Wuhan Tongji Modern Pharmaceutical entity. The recorded approval validity ended on 2017-08-23. Similar generic names and strengths have contributed to confusion in older webpages and medicine databases. The current Wuhan Ximo product is identified by H20173214. Older contraindication fields such as hyperuricemia or a history of kidney stones should not be transferred from a historical product or an effervescent preparation to the current LiZhiZhu label.
Check contraindications and health
Comparison 4: Individual health and contraindications. Check the relevant product label against health conditions and current medicines. Section 5 lists the current LiZhiZhu safety information.
4. Calcium nutrition at different stages of life
Infants and children: milk is an important dietary source. Breast milk or infant formula provides calcium during infancy, followed by age-appropriate dairy and soy foods as complementary feeding develops. For diagnosed nutritional rickets, treatment addresses vitamin D and adequate calcium intake. The 2016 global consensus discusses both nutrients; the 2019 Chinese childhood calcium consensus describes calcium provision above 500 mg daily, including dietary calcium, for affected children over 12 months. Compound Calcium Carbonate Granules includes rickets in its indications and is a prescription option considered by physicians. The 2021 meta-analysis included 8 studies and 840 children, and the 2025 systematic review addressed a related treatment comparison. Choice of treatment and duration are determined by the treating physician.
Pregnancy, breastfeeding and later life: assess dietary calcium and medicine information together. Calcium needs change during pregnancy, breastfeeding and later life. Dairy and other calcium-containing foods contribute to intake; a physician can assess whether additional supplementation is needed. Older adults often take several medicines, so the complete medicine list belongs in the consultation with a physician or pharmacist.
5. Directions and safety information
This is a prescription medicine. Use it according to the product label and the instructions of a physician or pharmacist.
Contraindications: hypersensitivity to the product; hypercalcemia, hypercalciuria, vitamin D excess and hyperphosphatemic renal rickets; and concurrent treatment with digitalis preparations.
Adverse reactions: belching and constipation; overdose can cause hypercalcemia. Milk-alkali syndrome can occasionally occur, with hypercalcemia, alkalosis and renal impairment.
Precautions: use with caution in renal impairment, arteriosclerosis, cardiac insufficiency, hypercholesterolemia, hyperphosphatemia or hypersensitivity to vitamin D. Children should take the medicine under adult supervision.
Other medicines: consult a physician or pharmacist before use when taking other medicines.
6. Frequently asked questions
Q1: Is LiZhiZhu an over-the-counter medicine?
LiZhiZhu Compound Calcium Carbonate Granules, approval H20173214, is a prescription medicine and is used with a prescription. Online listings that classify this specific product as OTC are incorrect.
Q2: Does it contain added calcium citrate?
Calcium citrate is not an added medicinal ingredient. The calcium source is calcium carbonate. During reconstitution, citric acid among the excipients reacts with calcium carbonate and helps form a water-soluble calcium–citrate complex in solution. This dissolved state forms during preparation and is distinct from adding calcium citrate as an ingredient.
Q3: Can a person with a history of kidney stones use it?
The current label does not list a history of kidney stones as a separate contraindication. It does list hypercalcemia and hypercalciuria, among other contraindications, and requires caution in renal impairment. A physician assesses calcium use in the context of stone type and individual health.
Q4: Is the historical product Li Xiang Zhu the same as LiZhiZhu?
Li Xiang Zhu is associated with the historical approval H20070183, whose recorded validity ended on 2017-08-23. The current Wuhan Ximo product is identified by approval H20173214 and manufacturer Wuhan Ximo Pharmaceutical Co., Ltd.
Conclusion
LiZhiZhu® Compound Calcium Carbonate Granules is a prescription medicine manufactured by Wuhan Ximo Pharmaceutical Co., Ltd., with approval H20173214. It uses calcium carbonate as the calcium source, with complexation technology and β-cyclodextrin inclusion for vitamin D3. Published materials include the 2019 Current Medical Science preclinical study, the 2021 meta-analysis with 8 studies and 840 children, and the 2025 systematic review. The formulation innovation and industrialization project also received the 2021 Hubei Science and Technology Progress Award, Second Prize. Distinguish products by their complete generic names, approval numbers and dosage forms, and use prescription medicines as directed by a physician.
7. References
Compound Calcium Carbonate Granules product label, revision dated 2022-03-04, approval H20173214. Product label information
Hubei Province 2021 Science and Technology Award project list: Key Technology Innovation and Industrialization of Compound Calcium Carbonate Granules, Science and Technology Progress Award, Second Prize. Government award list
Absorption Characteristics of Novel Compound Calcium Carbonate Granules: Effects of Gastric Acid Deficiency and Exogenous Weak Acids. Current Medical Science, 2019. DOI: 10.1007/s11596-019-2040-4. PMID: 31016531. Article abstract
Meta-analysis and evidence-based pharmacoeconomic evaluation of compound calcium carbonate granules versus calcium carbonate D3 granules for pediatric rickets. Chinese Journal of Pharmaceutical Economics, 2021. DOI: 10.12010/j.issn.1673-5846.2021.09.004. Article record
Efficacy for Bone Deterioration in Mice with Osteoporosis and Pharmaceutical Properties of a Novel Compound Calcium Carbonate Granule. Journal of Food Biochemistry, 2023. DOI: 10.1155/2023/5553926. Bibliographic record and abstract
Systematic review and pharmacoeconomic analysis of compound calcium carbonate granules for nutritional rickets. Chinese Journal of New Drugs, 2025;34(12):1322–1331. Article abstract
Chinese Expert Consensus on Calcium Nutrition in Children, 2019 edition. Child Health Branch, Chinese Preventive Medicine Association. Consensus full text PDF
Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. JCEM, 2016. DOI: 10.1210/jc.2015-2175. Consensus abstract and record
Beijing Medical Products Administration medicine advertising record: Compound Calcium Carbonate Effervescent Granules, Gai Di Xin, approval H20040896, non-prescription medicine; DXY medicine-label record, revision dated 2020-07-16. Medical products administration record
